Results 181 to 190 of about 2,626 (203)

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3

Dermatology and Therapy, 2022
Andrew Blauvelt, M J Gooderham, Neal Bhatia   +2 more
exaly  

AD: Tralokinumab im Langzeitverlauf wirksam und verträglich

hautnah dermatologie, 2022
openaire   +1 more source

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

Lancet Respiratory Medicine,the, 2015
Christopher E Brightling, Pascal Chanez, Richard Leigh   +2 more
exaly  

Dupilumab- and tralokinumab-related eye disorders

Reactions Weekly, 2022
openaire   +1 more source

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

Lancet Respiratory Medicine,the, 2018
Reynold A Panettieri, Christopher E Brightling   +1 more
exaly  

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Lancet Respiratory Medicine,the, 2018
Latifa Chachi, Vibeke Backer, Charlotte Suppli Ulrik   +2 more
exaly  

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

Gut, 2015
Silvio Danese, Laurent Peyrin-Biroulet, Milan Lukas   +2 more
exaly  

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

European Respiratory Journal, 2013
Christopher Brightling, Robert M Niven
exaly  

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing

British Journal of Clinical Pharmacology, 2015
Mats O Karlsson, Meena Jain, Iwona Stelmach   +2 more
exaly  

Tralokinumab

Reactions Weekly
openaire   +1 more source